---
title: Dutch medtech companies gain access to the heart of the US healthcare market
date: 2026-09-30T16:41:00+02:00
author: Ingrid Nagtzaam
canonical_url: "https://www.bom.nl/en/articles/nederlandse-medtech-bedrijven-krijgen-toegang-tot-het-hart-van-de-amerikaanse-zorgmarkt"
section: Articles
---
#  Dutch medtech companies gain access to the heart of the US healthcare market 

 Impact story 

 

 Twelve promising Dutch medtech companies will join the BioBridge programme of the renowned Texas Medical Center (TMC), giving them a unique opportunity to establish a foothold in the United States and take critical steps towards clinical validation and market entry. 

 

 

 

 

 

   ![IMG 8328 edited](https://d3d5gk1jdgmand.cloudfront.net/resized/_900x600_crop_center-center_none_ns/151699/IMG_8328_edited.webp)  

   

 

 

  

 

“To succeed as a medtech company, you need to think and operate internationally,” says **Mike Houtkamp**, National Trade Advisor Health at the Brabant Development Agency (BOM).

Together with **Sasja Heijman**, Account Manager Foreign Investments &amp; International Trade at InnovationQuarter, Houtkamp helped lay the foundation for the first Dutch participation in the programme. “BioBridge can be transformative for companies,” says Sasja. “Participants receive intensive support over an extended period. Texas Medical Center gives them the guidance, network, and expertise they need to move toward market adoption. They are introduced to key opinion leaders, physicians and hospitals, helping them work towards demonstrations, pilot projects and future collaborations.”

 

 

> “BioBridge can be transformative for companies. Participants receive intensive support over an extended period. TMC provides the guidance, network and expertise they need to accelerate towards market adoption. They are introduced to key opinion leaders, physicians and hospitals, helping them work towards demonstrations, pilot projects and future collaborations.

###### Sasja Heijman

Account Manager Foreign Investments &amp; International Trade at InnovationQuarter (IQ)

 

 

 

 

 

 

 

## Learn more

   ![Mike Houtkamp 25](https://d3d5gk1jdgmand.cloudfront.net/resized/employees/_500x500_crop_center-center_none_ns/130360/Mike-Houtkamp-25.webp)  

  

### Mike Houtkamp

National Trade Advisor - Health

  

- [  Phone ](tel:+31621935847)
- [  Email ](mailto:mhoutkamp@bom.nl)
- [  Chat via Teams ](https://teams.microsoft.com/l/chat/0/0?users=mhoutkamp@bom.nl)
 
 

 

 

 

 

 

 

 

 

 

 

 

    

 

 

   ![12 bedrijven](https://d3d5gk1jdgmand.cloudfront.net/resized/_726xAUTO_crop_center-center_none_ns/152931/12-bedrijven.webp)  

## From blueprint to implementation

The seven-month programme will begin in October 2026. During that period, participants will travel to Houston three times and receive hands-on guidance from experts across the Texas Medical Center ecosystem. The first visit focuses on developing a blueprint for entering the US market, covering critical topics such as the healthcare system, procurement processes, business models and regulatory requirements. During the second visit, companies will translate these insights into their commercial and market-entry strategies. The final visit is dedicated to refining US market access plans, exploring partnership opportunities, advancing potential hospital pilot projects and building relationships with prospective investors.

 

 

 

 

 

> Through our collaboration with TMC, we want to offer Dutch companies a faster and more accessible route into the US healthcare market. Ultimately, this could also help accelerate market adoption in Europe.

###### Mike Houtkamp

 

 

 

 

 

 

### The challenge of the European market

“The US market is larger and more centrally organised,” says Mike. “Europe, by contrast, consists of many different markets. While medical products can receive EU-wide approval, reimbursement systems differ from country to country. On top of that, the regulatory environment is highly complex.” According to Mike, the Dutch healthcare landscape adds another layer of fragmentation.“A successful implementation in one hospital does not automatically lead to adoption by others. Procurement, implementation and decision-making largely take place at the institutional level,” he explains. He emphasises that thorough testing before market introduction is essential, given the direct impact medical technologies can have on people’s lives. “The challenge is not only regulatory. It also involves navigating significant differences between countries, healthcare systems, and decision-making structures. For young companies, that makes international scaling both complex and costly.”

 

 

   ![IMG 2488](https://d3d5gk1jdgmand.cloudfront.net/resized/_726xAUTO_crop_center-center_none_ns/154138/IMG_2488_2026-10-13-140158_vhya.webp)  

## The investment landscape

Investment conditions also influence growth opportunities. “Validating a medical product and achieving rapid growth require substantial capital. In the US, investors are generally more willing to make larger investments than in Europe,” says Mike. He believes the Netherlands excels at developing innovative medical technologies but often faces challenges when it comes to commercialisation. “Bringing these innovations to market requires an international perspective. That is reflected in the funding landscape as well. In the Netherlands, there is relatively strong support for research and development through grants and public funding, but a shortage of capital for scaling innovations. As a result, excellent technologies sometimes fail to reach the market.”

 

 

 

 

## Building an important bridge

Given these realities, it is not surprising that many companies look towards the United States, says Sasja. “That does not mean they are leaving the Netherlands behind. These companies have developed their intellectual property here and often work closely with universities and academic hospitals. The Netherlands remains their home base. Depending on their strategy, establishing a presence in the US may become a logical next step.” Mike adds: “Through our collaboration with Texas Medical Center, we want to offer Dutch companies a faster and more accessible route into the US healthcare market. Ultimately, this could also help accelerate market adoption in Europe.” He even sees broader opportunities. “We want BioBridge to become a bridge that works in both directions. On one side, Dutch companies gain access to the Texas healthcare ecosystem. On the other, the programme showcases opportunities for American companies to establish operations in the Netherlands, strengthening our life sciences and health ecosystem.” Sasja agrees: “We are actively looking to create a truly reciprocal partnership.”

 

 

 

> Both public and private partners were willing to join forces. We are now seeing the real power of that collaboration.

###### Mike Houtkamp

 

 

 

 

 

 

### Turning ambition into reality

A partnership with Texas Medical Center had long been an ambition within the Dutch life sciences and health ecosystem. Thanks to the combined efforts of organisations including BOM, InnovationQuarter, Health~Holland, Task Force Health Care and Invest International, that ambition has now become reality. “Both public and private partners were willing to join forces,” says Mike. “We are now seeing the real power of that collaboration.” The programme brings together expertise from across the Dutch innovation ecosystem. Health~Holland, the regional development agencies and other partners each contribute from their own perspective, supporting companies in innovation, financing, market development and internationalisation.

 

 

   ![Collaboration](https://d3d5gk1jdgmand.cloudfront.net/resized/_726xAUTO_crop_center-center_none_ns/152939/collaboration.webp)  

## The power of the ecosystem

“We need all partners to make this programme a success,” says Sasja. “Every organisation plays a different role. Strong relationships are being built, not only for this programme but also for future collaborations.” For both organisers, that collaboration provides additional motivation. “It is incredibly rewarding to see a programme grow from exploratory discussions into a fully realised initiative with such motivated and committed entrepreneurs,” says Mike.

 

 

 

 

## Entrepreneurs learning from one another

The programme has attracted strong interest from the Dutch medtech sector. During the application process, 35 companies applied. Following a joint selection process involving Texas Medical Center and all programme partners, twelve companies were chosen to participate. Sasja emphasises that the success of the cohort is determined not only by the performance of individual companies, but also by the strength of the group as a whole. That is why a deliberately diverse cohort was assembled, including university spin-offs alongside serial entrepreneurs who have already founded and scaled multiple businesses. Although the companies differ in technology, background and experience, they face many of the same challenges when entering the US market. “That is exactly why peer-to-peer learning is such an important part of the programme,” says Sasja. “The participants can genuinely help one another move forward.”

 

 

 

> This programme brings together the core strengths of the regional development agencies. Innovation and ecosystem development create the foundation for startup activity. We then invest in promising companies and support their international growth ambitions. To do so, we work not only with the Dutch innovation ecosystem, but also with international partners, including embassies, consulates and the Netherlands Business Support Offices (NBSOs).

###### Mike Houtkamp

 

 

 

 

 

 

   ![Shutterstock 2515101105 2026 09 30 145324 tlnu](https://d3d5gk1jdgmand.cloudfront.net/resized/_726xAUTO_crop_center-center_none_ns/154144/shutterstock_2515101105_2026-09-30-145324_tlnu_2026-10-13-141821_ipvv.webp)  

## More about the strategy and partnership

Mike and Sasja have worked closely over the past several years to make Dutch participation in TMC’s prestigious programme possible. “Five other countries, including Australia and the United Kingdom, have already been participating in BioBridge for several years,” says Mike. “Now the Netherlands is officially joining them.” The partnership with Texas Medical Center began in 2023 with the signing of a Memorandum of Understanding (MoU) between Health~Holland and Texas Medical Center. As part of that collaboration, Task Force Health Care was appointed as implementation partner. Within the framework of the Dutch government's Strategic Multi-Year Market Approach (SMM) for Texas and California, coordinated by the Netherlands Enterprise Agency (RVO), stakeholders explored concrete ways to provide Dutch companies with access to the US healthcare market.

As part of that effort, the regional development agencies united under ROM-Nederland were tasked with investigating how Dutch companies could access the TMC BioBridge model. On behalf of ROM-Nederland, Mike Houtkamp (BOM), acting as national coordinator, and Sasja Heijman (InnovationQuarter) conducted an extensive study. Their conclusion was clear: Dutch medtech companies need a structured pathway into the US market, including access to clinical validation, investors and market intelligence. That recommendation became the foundation for the first Dutch cohort participating in the BioBridge programme. Invest International, the Dutch public-private financing institution, also played a key role. The organisation aims to help Dutch businesses expand internationally. “I am proud to see how we have evolved from a strategic plan into a strong programme that enables us to showcase both the Netherlands as a whole and our most promising companies on the international stage,” says Sasja. The programme brings together expertise from across the Dutch innovation ecosystem. Health~Holland, the regional development agencies and other partners each contribute from their own perspective, supporting companies in innovation, financing, market development and internationalisation.

 

  

 

 

*Over the coming months, we will follow the twelve entrepreneurs throughout their journey to Texas Medical Center. We will share their experiences, the opportunities they encounter, the challenges they face, and the role the Dutch ecosystem plays in supporting their ambitions. Curious to learn more? Follow our website and LinkedIn page for the next chapter.*
